- Home
- SOPH vs OBIO Comparison
SOPH vs OBIO Comparison
Compare SOPH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- OBIO
- Stock Information
- Founded
- SOPH 2011
- OBIO 2017
- Country
- SOPH Switzerland
- OBIO United States
- Employees
- SOPH N/A
- OBIO N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SOPH Health Care
- OBIO Health Care
- Exchange
- SOPH Nasdaq
- OBIO Nasdaq
- Market Cap
- SOPH 193.8M
- OBIO 118.8M
- IPO Year
- SOPH 2021
- OBIO N/A
- Fundamental
- Price
- SOPH $3.25
- OBIO $2.89
- Analyst Decision
- SOPH Buy
- OBIO Strong Buy
- Analyst Count
- SOPH 1
- OBIO 5
- Target Price
- SOPH $7.00
- OBIO $14.20
- AVG Volume (30 Days)
- SOPH 175.7K
- OBIO 386.4K
- Earning Date
- SOPH 08-05-2025
- OBIO 08-11-2025
- Dividend Yield
- SOPH N/A
- OBIO N/A
- EPS Growth
- SOPH N/A
- OBIO N/A
- EPS
- SOPH N/A
- OBIO N/A
- Revenue
- SOPH $67,173,000.00
- OBIO $2,886,000.00
- Revenue This Year
- SOPH $16.07
- OBIO $20.47
- Revenue Next Year
- SOPH $22.94
- OBIO $11.45
- P/E Ratio
- SOPH N/A
- OBIO N/A
- Revenue Growth
- SOPH 4.66
- OBIO 30.23
- 52 Week Low
- SOPH $2.58
- OBIO $2.37
- 52 Week High
- SOPH $4.92
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- SOPH 58.30
- OBIO 46.36
- Support Level
- SOPH $2.99
- OBIO $2.60
- Resistance Level
- SOPH $3.40
- OBIO $2.94
- Average True Range (ATR)
- SOPH 0.28
- OBIO 0.26
- MACD
- SOPH 0.01
- OBIO -0.03
- Stochastic Oscillator
- SOPH 81.08
- OBIO 32.95
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.